HOME
FACULTY
2023 CONFERENCE AGENDA
PROSPECTUS
SPONSORS
TESTIMONIALS
CONTACT
More
ARTICLES:
FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-Free Survival in People With Unresectable Hepatocellular Carcinoma